Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28261765 | 0.85 | CYP11B1 (0.49) | LTA4HCYP11B1CYP11B2ALDH1A1CYP1A2 | |
| SCHEMBL10585037 | 0.83 | — | — | |
| SCHEMBL4464494 | 0.80 | CYP11B1 (0.47) | MEN1KMT2ALTA4HCYP11B1CYP11B2 | |
| Ammonia Solution, Strong SCHEMBL27704656 | 0.79 | GPR55 (0.51) | LTA4HCYP11B1CYP11B2 | |
| SCHEMBL7213235 | 0.79 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL2355103 | 0.78 | LTA4H (0.71) | MEN1KMT2ALTA4HCYP11B1CYP11B2 | |
| SCHEMBL3837906 | 0.78 | GPR55 (0.49) | CYP1A2HSD17B10 | |
| SCHEMBL29041232 | 0.78 | CYP11B1 (0.48) | MEN1KMT2ALTA4HCYP11B1CYP11B2 | |
| SCHEMBL29162297 | 0.77 | CYP11B1 (0.45) | MEN1KMT2ALTA4HCYP11B1CYP11B2 | |
| SCHEMBL28872975 | 0.77 | LTA4H (0.57) | LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142253-A1 | Dithiolane Based Thiol Modifier For Labeling and Stronger Immobilization of Bio-Molecules On Solid Surfaces | CHEMGENES CORPORATION (US) | 2014-05-22 | — | — | US | claimed |
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | claimed |
| WO-2013126034-A1 | SYNTHESIS OF HIGH PURITY DMT-C3-DISULFIDE PHOSPHORAMIDITE | CHEMGENES CORPORATION (US) | 2013-08-29 | — | — | WO | claimed |
| EP-2560982-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | Chemgenes Corporation (US) | 2013-02-27 | — | — | EP | claimed |
| WO-2011103468-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | CHEMGENES CORPORATION (US) | 2011-08-25 | — | — | WO | claimed |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | CHEMGENES CORPORATION (US) | 2011-06-09 | — | — | US | claimed |
| EP-2121719-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | Alios Biopharma, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2009086192-A1 | BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2009086201-A1 | 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2008095040-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-6239220-B1 | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | claimed |
| US-6124484-A | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | claimed |
| WO-2000004062-A1 | RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| EP-3160475-B1 | SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE INFECTIONS | JANSSEN PHARMACEUTICALS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2000004062-A1 | RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| EP-0144386-B1 | NOVEL PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITE INTERMEDIATES | BECKMAN INSTRUMENTS, INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0144386-A1 | NOVEL PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITE INTERMEDIATES. | BECKMAN INSTRUMENTS INC (US) | 1985-06-19 | — | — | EP | disclosed |
| WO-1984004749-A1 | NOVEL PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITE INTERMEDIATES | BECKMAN INSTRUMENTS INC (US) | 1984-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142253-A1 | Dithiolane Based Thiol Modifier For Labeling and Stronger Immobilization of Bio-Molecules On Solid Surfaces | PTMS, SPOUT1, SRMS | MEN1 3941/4885KMT2A 3039/4885LTA4H 3176/4885 |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | NSUN3, RNGTT, NOP2 | MEN1 3293/4885KMT2A 1614/4885LTA4H 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.